Nomura Asset Management Co. Ltd. Has $16.03 Million Stock Position in Edwards Lifesciences Co. (NYSE:EW)

Nomura Asset Management Co. Ltd. lifted its holdings in shares of Edwards Lifesciences Co. (NYSE:EW) by 7.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 216,517 shares of the medical research company’s stock after purchasing an additional 15,014 shares during the period. Nomura Asset Management Co. Ltd.’s holdings in Edwards Lifesciences were worth $16,029,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP increased its position in Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after purchasing an additional 14,610,123 shares during the period. Norges Bank acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $610,895,000. Jennison Associates LLC bought a new position in Edwards Lifesciences during the fourth quarter worth $555,939,000. Vanguard Group Inc. lifted its holdings in Edwards Lifesciences by 10.4% in the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after buying an additional 6,537,494 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in Edwards Lifesciences by 475.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock valued at $314,182,000 after buying an additional 3,506,886 shares during the period. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $70.90 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The firm has a 50-day moving average of $71.49 and a 200-day moving average of $70.53. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.73. The company has a market cap of $41.68 billion, a P/E ratio of 10.17, a P/E/G ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. Equities research analysts forecast that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Morgan Stanley lifted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Citigroup boosted their price target on Edwards Lifesciences from $81.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Bank of America raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Wolfe Research downgraded shares of Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Finally, Barclays raised their price target on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $79.95.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 500 shares of the business’s stock in a transaction dated Thursday, January 16th. The shares were sold at an average price of $68.76, for a total value of $34,380.00. Following the transaction, the vice president now directly owns 23,189 shares in the company, valued at $1,594,475.64. The trade was a 2.11 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Bernard J. Zovighian sold 6,164 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $69.51, for a total transaction of $428,459.64. Following the sale, the chief executive officer now owns 59,083 shares of the company’s stock, valued at approximately $4,106,859.33. The trade was a 9.45 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 62,553 shares of company stock valued at $4,513,064. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.